Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
3 minute read
  • Biotech
  • General
  • News

Kineta To Host KOL Event To Review New Data From VISTA-101 Clinical Trial Of KVA12123 In Patients With Advanced Solid Tumors On December 5, 2023

By Benzinga Newsdesk
November 28, 9:31 AM
Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will host a virtual KOL

KA

Read More
3 minute read
  • Biotech
  • General
  • Global
  • News

BioMarin Announces Agreement With German Health Insurance Fund On Reimbursement Amount For ROCTAVIAN For Severe Hemophilia A In Germany

By Benzinga Newsdesk
November 28, 9:31 AM
ROCTAVIAN is First Gene Therapy for Hemophilia to Receive Approved Federal Price in GermanySAN RAFAEL, Calif., Nov. 28, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a global biotechnology company

BMRN

Read More
2 minute read
  • Biotech
  • General
  • News

Ensysce Biosciences And OncoZenge Announce Letter Of Intent For The Co-Development Of BupiZenge In The U.S.

By Benzinga Newsdesk
November 28, 9:25 AM
Collaboration Aims to Accelerate Development of BupiZenge™, a Novel Pain Treatment for Oral Mucositis Associated with Cancer TreatmentSAN DIEGO, CA and STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / Ensysce

ENSC

Read More
3 minute read
  • Biotech
  • General
  • News

Sol-Gel Technologies Ltd To Host Virtual KOL Event On Gorlin Syndrome And The Upcoming Phase 3 Trial For SGT-610

By Benzinga Newsdesk
November 28, 9:21 AM
Event to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a discussion of the disease burden, SGT-610 and the upcoming Phase 3 trial NESS ZIONA, Israel,

SLGL

Read More
2 minute read
  • Biotech
  • General
  • News

ReWalk Robotics Demonstrates AI Autonomous Decision Making In Next Generation Exoskeleton Prototype

By Benzinga Newsdesk
November 28, 9:14 AM
ReWalk Robotics, Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological

RWLK

Read More
2 minute read
  • Biotech
  • General
  • News

Locafy Announces First Trial Results From Preliminary Article Accelerator Implementation For U.S.-Based Media Publisher

By Benzinga Newsdesk
November 28, 9:13 AM
Locafy Article Accelerator, Based on Locafy's Keystone Technology, Displays Promising Results in First Round of Preliminary TrialsU.S.-Based Media Publisher Expects to Incorporate Product Across Network RosterPERTH,

LCFY

Read More
3 minute read
  • Biotech
  • Events
  • General
  • Global
  • News

Perspective Therapeutics Announces First Ever Human SPECT Imaging Of Pb-212 With VMT-α-NET By Clinical Collaborators In Germany

By Benzinga Newsdesk
November 28, 9:11 AM
Imaging was conducted as part of a clinical study at Technical University of Dresden in Germany Image was selected as "Image of the Month" in the European Journal of Nuclear Medicine and Molecular Imaging, November

CATX

Read More
1 minute read
  • Biotech
  • Events
  • General
  • News

Sagimet Biosciences Announces Oral Presentation Of Preclinical Results Of FASN Inhibitor In Combination With Semaglutide At The 7th Obesity And NASH Drug Development Summit

By Benzinga Newsdesk
November 28, 9:10 AM
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways, will present preclinical

SGMT

Read More
3 minute read
  • Biotech
  • General
  • News

Phathom Pharmaceuticals Announces Commercial Availability Of VOQUEZNA Tablets, A Powerful First-In-Class PCAB For The Treatment Of Erosive GERD And Relief Of Associated Heartburn

By Benzinga Newsdesk
November 28, 9:06 AM
VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end digital fulfillment channel VOQUEZNA tablets

PHAT

Read More
1 minute read
  • Biotech
  • Exclusives
  • General
  • Health Care
  • News
  • Penny Stocks

EXCLUSIVE: Clearmind Medicine’s Psychedelic-Based Treatment Shows Encouraging Preclinical Activity In Obesity, Metabolic Disorders

By Vandana Singh
November 28, 9:00 AM
Clearmind Medicine Inc (NASDAQ: CMND) has released results from its pre-clinical trial of the combination therapy.

CMND

Posts pagination

Previous 1 … 191 192 193 … 795 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service